Skip to main navigation Skip to search Skip to main content

Phase II doseselection, randomized double-blind trial of the ASI, BI 690517, alone and in combination with EMPA in people with CKD

Research output: Other contribution

Abstract

This study is investigating the efficacy and safety of three doses of BI 690517, alone and in combination with empagliflozin (EMPA), on top of an ACEi or ARB, for treatment of CKD with or without type 2 diabetes. This study will provide key data on the potential synergistic kidney-protective effects and safety of combination therapy with BI 690517 plus EMPA, as well as data on monotherapy, for CKD with or without type 2 diabetes. Findings will inform BI 690517 dose selection for further clinical trial development.

Original languageUndefined/Unknown
StatePublished - Jun 1 2023

Publication series

NameArticles, Abstracts, and Reports

Cite this